Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balstilimab in Relapsed/Refractory Lymphomas
NCT05891821Phase 2Recruiting
- Sponsor
- Immune Oncology Research Institute
- Start
- Sep 2023
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of balstilimab in classical Hodgkin lymphoma (cHL) and Primary Mediastinal B-Cell Lymphoma (PMBCL), sponsored by Immune Oncology Research Institute. Primary endpoint: Objective Response Rate up to 27 months. Started Sep 2023; status: recruiting.
02
Drugs
balstilimab
03
Conditions
classical Hodgkin lymphoma (cHL)Primary Mediastinal B-Cell Lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT05891821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891821.